Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 7/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974783 | 0.83 | CDK8 (0.47) | CDK2CDK9MAP4K4 | |
| SCHEMBL2973238 | 0.82 | HSD17B1 (0.46) | METAP2MAP4K4 | |
| SCHEMBL2974909 | 0.82 | BIRC5 (0.50) | IDO1METAP2 | |
| SCHEMBL2979465 | 0.78 | CYP2A6 (0.49) | KITCCNT1CCNA2CDK2CDK9 | |
| SCHEMBL2975272 | 0.76 | CYP1A2 (0.34) | — | |
| SCHEMBL2978668 | 0.74 | CLK1 (0.43) | KITCCNT1CCNA2CDK2CDK9 | |
| SCHEMBL2981890 | 0.74 | NPC1 (0.38) | CDK2METAP2MAP4K4 | |
| SCHEMBL2981228 | 0.73 | MAPK8 (0.45) | — | |
| SCHEMBL2979016 | 0.71 | CA12 (0.43) | GRIN1GRIN2BCCNT1CCNA2CDK2 | |
| SCHEMBL2977491 | 0.71 | RIPK1 (0.54) | GRIN1GRIN2BKITGAKEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| EP-1675853-B1 | IMIDAZO(4,5-B)PYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-18 | — | — | EP | disclosed |
| US-20080108652-A1 | Imidazo (4,5-B) pyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG | 2008-05-08 | — | — | US | disclosed |
| US-7329677-B2 | Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20070010549-A1 | Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-01-11 | — | — | US | disclosed |
| EP-1675853-A1 | IMIDAZO(4,5-B)PYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1670798-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | Altana Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061496-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005030768-A1 | IMIDAZO(4,5-B)PYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | NOS2, NOS1, NOS3 | GRIN1 468/4885GRIN2B 495/4885KIT 1744/4885 |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | GRIN1 468/4885GRIN2B 495/4885KIT 1744/4885 |
| US-20080108652-A1 | Imidazo (4,5-B) pyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | GRIN1 1086/4885GRIN2B 1304/4885KIT 1727/4885 |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | NOS2, NOS1, NOS3 | GRIN1 623/4885GRIN2B 607/4885KIT 2501/4885 |
| US-20070010549-A1 | Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | GRIN1 1086/4885GRIN2B 1304/4885KIT 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.